CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the start of patient dosing in an international Phase 1/2 clinical trial of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) -- two clinically validated targets in non-small cell lung cancer (NSCLC). AP26113 is the third novel, small-molecule drug candidate for the treatment of cancer that was discovered by ARIAD scientists and has advanced into clinical development.
